FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O ZYV	Robert G  (Fi VERSA TH COMMERC	irst) ERAPEUTICS, CE PARKWAY,		3	3. E	2. Issuer Name and Ticker or Trading Symbol  ZyVersa Therapeutics, Inc. [ ZVSA ]  3. Date of Earliest Transaction (Month/Day/Year)  12/12/2022  4. If Amendment, Date of Original Filed (Month/Day/Year)							(C	Meck all applie  X Directe Officer below)  Individual or viet X Form f	cable) or (give title  Joint/Group filed by One	ng Person(s) to Issuer  10% Owner Other (spec below)  p Filing (Check Applica ne Reporting Person ore than One Reporting		plicable
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D)  Table II - Derivati				action Day/Ye	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transac Code (Ir 8) Code	tion istr.	4. Securit Disposed 5)  Amount	(A) or Bend	ed (A) or tr. 3, 4 an Price	5. Amount of Securities I Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,	A. Transaction Code (Instr. 8)		5. Number		6. Date Exercisal Expiration Date (Month/Day/Year		of Securities		d Amounties g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				C	Code	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares					
Stock Options (right to buy)	\$11.58	12/12/2022			A		29,781		(1)	04	1/02/2029	Common Stock	29,781	\$0	29,781	Į.	D	
Stock Options (right to buy)	\$16.36	12/12/2022			A		19,854		(2)	02	2/08/2031	Common Stock	19,854	\$0	19,854		D	
Stock Options (right to buy)	\$16.36	12/12/2022			Α		9,927		(3)	01	/28/2032	Common Stock	9,927	\$0	9,927		D	

## **Explanation of Responses:**

- 1. 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
- 2. The option vests in 3 equal annual installments commencing on February 8, 2022.
- 3. The option vests in 3 equal annual installments commencing on January 28, 2023.

/s/ Peter Wolfe, attorney-in-fact for Robert G. Finizio 12/14/2022

\*\* Signature of Reporting Person D

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.